2023 World Conference on Lung Cancer (Posters)-P2.04. AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) + Durvalumab + Carboplatin as 1L Treatment of Advanced/mNSCLC

P2.04. AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) + Durvalumab + Carboplatin as 1L Treatment of Advanced/mNSCLC - PDF(Slides)

Back to course

Pdf Summary

The AVANZAR study is a Phase III clinical trial investigating the use of datopotamab deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin as a first-line treatment for advanced/metastatic non-small-cell lung cancer (NSCLC). Dato-DXd is an antibody-drug conjugate that targets the protein TROP2, which is often overexpressed on lung cancer tumors. The drug consists of an antibody that binds to TROP2 and an anticancer drug that is released inside the tumor cell to kill the tumor. The purpose of the study is to evaluate whether this combination therapy can improve progression-free survival (PFS) and overall survival (OS) compared to standard treatments.<br /><br />The study aims to enroll approximately 1,000 patients with locally advanced or metastatic NSCLC who have not received any prior first-line treatment. The patients will be randomly assigned to receive either Dato-DXd, durvalumab, and carboplatin, or pembrolizumab (another immunotherapy) in combination with histology-specific chemotherapy. The patients will continue to receive their designated treatments as long as the tumor is controlled and there are no unacceptable side effects.<br /><br />Previous studies have shown promising antitumor activity with Dato-DXd monotherapy or in combination with immunotherapy and chemotherapy. The AVANZAR study will assess the efficacy and safety of adding Dato-DXd to the standard treatment regimen for advanced NSCLC. The primary endpoints of the study are PFS and OS in the TROP2-positive population. Secondary endpoints include objective response rate, duration of response, and safety and tolerability.<br /><br />The study is currently ongoing and is expected to be completed in May 2027. The results of this study will provide valuable insights into the potential benefit of Dato-DXd in combination with immunotherapy and chemotherapy as a first-line treatment option for patients with advanced/metastatic NSCLC.

Asset Subtitle

Terufumi Kato

Meta Tag

Speaker Terufumi Kato

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

AVANZAR study

Phase III clinical trial

Dato-DXd

TROP2 protein

combination therapy

progression-free survival

overall survival

first-line treatment

immunotherapy

chemotherapy